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Risk factors in idiopathic renal vasculitis and glomerulonephritis. In
this retrospective study, we analyzed clinical laboratory, and patho-
logic variables to determine their value in predicting survival and
survival free of renal failure for 170 consecutive patients with idiopathic
renal vasculitis and glomerulonephritis evaluated during a 15 year
period. Of the 170 patients, 108 had focal segmental necrotizing
glomerulonephritis alone (FSNGN), 33 had FSNGN and small-artery
vasculitis, and 29 had FSNGN and medium-sized artery vasculitis.
Considerable overlap of clinical, laboratory, and pathologic findings
existed among the three groups. Overall patient survival was 81% at one
year, 61% at five years, and 44% at ten years, significantly less than
expected survival. Overall survival free of renal failure, by definition,
was lower than patient survival. There were no differences among these
three groups in patient survival or survival free of renal failure.
Multivariate analysis identified leukocytosis and serum creatinine level
as independent predictors of patient survival and survival free of renal
failure. In addition, univariate analysis identified age and hypertension
as significant risk factors but did not add independent predictive value
for these two end points. In patients with serum creatinine levels < 4
mg/dl, the effect of increasing levels of leukocyte count was signifi-
cantly associated with poorer outcomes for both patient survival (P =
0.006) and survival free of renal failure (P = 0.024). Outcomes for these
two end points were worse for patients with lower serum creatinine
levels (< 4.0 mgldl) and high leukocyte counts (> 16,000/mm') than for
those with serum creatinine levels  4.0 mg/dl.
Renal involvement is an important clinical manifestation of
systemic necrotizing vasculitis [1—4]. Renal biopsy commonly
yields the pathologic diagnosis of focal segmental necrotizing
glomerulonephritis, either with or without evidence of vessel
necrosis beyond the level of the glomerular capillary [4, 5].
Vessel involvement beyond the glomerular capillary is difficult
to prove by biopsy, even in patients with signs and symptoms
suggestive of systemic necrotizing vasculitis and aggressively
evaluated with biopsies of renal and extrarenal tissue [4—6]. The
importance of biopsy-proven arteriolar or arterial involvement
in patients with focal segmental necrotizing glomerulonephritis
is not clear [7—12].
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One important problem in the management of patients with
idiopathic renal vasculitis is to identify those who are at high
risk of either death or renal failure so that treatment can be
designed to prevent these major events. We and others have
shown that it is possible to identify variables that predict
important differences in renal function and patient outcome in
patients with the same parenchymal renal disease. Leukocyto-
sis may be an important risk factor in ischemic diseases [9], but,
to our knowledge, no specific studies of vasculitis have been
reported. This may be relevant because other studies that
demonstrate antibodies directed against neutrophil cytoplasmic
components in serum from patients with systemic vasculitis
[10—12] (Cohen Tervaert JW, van der Woude FJ, Fauci AS,
Ambrus JL, Velosa JA, Keane WF, Sijtze M, van der Giessen
M, The TH, van der Hem GK, Kallenberg CGM, unpublished
data) have focused attention on the importance of inflammatory
cells in vasculitis [13]. Furthermore, recent studies suggest that
autoantibody-mediated activation of neutrophils may be impor-
tant in the pathogenesis of vasculitis [14, 15].
The purposes of this study were to assess: 1) the outcome of
three groups of patients with idiopathic vasculitis and glomer-
ulonephritis according to the size of vessel involved; and 2) the
association among clinical, laboratory, and pathologic variables
and patient survival and survival free of renal failure.
Methods
Patients
All patients were selected using the renal biopsy report files
in the Mayo Clinic Medical Diagnostic Index covering a period
of 15 years (1970—1984). The selection of patients was based on
biopsy evidence of focal segmental necrotizing glomerulone-
phritis with or without renal or extrarenal vasculitis.
Excluded were patients with systemic lupus erythematosus,
Henoch-Schonlein purpura, IgA nephropathy, rheumatoid vas-
culitis, Wegener' s granulomatosis, relapsing polychondritis,
cryoglobulinemia, hypocomplementemic vasculitis, and postin-
fectious glomerulonephritis including endocarditis. Antiglomer-
ular basement membrane disease was excluded based on direct
immunofluorescence of renal biopsy or serum determination of
antiglomerular basement membrane antibodies or both. Diffuse
immune complex crescentic glomerulonephritis was excluded
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based on immunofluorescence or electron microscopy. Two
patients were excluded because of a second type of glomerular
disease—that is, diabetic nephropathy or focal segmental gb-
merulonephritis—associated with the nephrotic syndrome.
The study group consisted of 170 consecutive patients with
idiopathic renal vasculitis evaluated at the Mayo Clinic from
1970 through 1984: 108 patients with focal segmental necrotiz-
ing glomerulonephritis, 33 with focal segmental necrotizing
glomerulonephritis and small-artery vasculitis, and 29 with
focal segmental necrotizing glomerulonephritis and medium-
sized artery vasculitis. All laboratory tests, specifically serum
creatinine level, leukocyte count, and differential counts, were
determined by standard techniques used in the clinical labora-
tories of the Mayo Clinic. The leukocyte counts were per-
formed the first day of the patient's evaluation, before treat-
ment, using automated equipment; the coefficient of variation
was <2%. Records were reviewed to establish whether patients
had an associated bacterial infection or were taking prednisone
at the time the leukocyte count was determined.
Definitions
Vasculitis was defined by the presence of fibrinoid necrosis
and acute inflammatory cellular infiltrate within the wall of the
vessel in any vessel other than the glomerular capillary. Focal
segmental necrotizing glomerulonephritis was defined as the
presence of necrosis involving glomerular capillaries in some
but not all glomeruli (focal) or usually involving a segment of
the glomerulus (segmental). Changes include disruption of
capillary wall, presence of fibrinoid necrosis, increase in poly-
morphonuclear leukocytes, variable endocapillai-y cell in-
crease, and frequent crescents. We consider focal segmental
necrotizing glomerulonephritis a form of vasculitis involving
glomerular capillaries. For survival analysis, time 0 was defined
as the date of presentation to our institution. Two end points
were studied: survival to death from any cause and survival free
of renal failure. The latter end point was defined as the date of
the first occurence of any of the following: serum creatinine
level >10 mgldl, renal transplantation, chronic hemodialysis, or
death from any cause. Elevated blood pressure was defined as
diastolic blood pressure >95 mm Hg at initial evaluation.
Methods of preparing renal tissue for light microscopy and
immunofluorescence were as previously described [16]. His-
tologic sections were read blind. Renal tissue was examined,
and semiquantitative analysis was performed with light micros
copy. The size of the vessel involved with vasculitis was
determined in both renal and extrarenal tissues (when available)
by light microscopy. No attempt was made to classify the size
of artery involvement by angiography because it was not used
in the workup of these patients. The immunofluorescence data
were abstracted from the renal pathology filing system. Immu-
nofluorescence findings were graded 1 to 3 + for each of four
locations: mesangial, capillary wall, vessel wall, and tubules.
The following characteristics of renal tissue were quantified on
light microscopy preparations: total number of glomeruli, num-
ber of sclerosed glomeruli, number of glomeruli with active
segmental necrotizing lesions, number of crescents (cellular,
fibrocellular, or fibrotic), and number of arterioles, intralobular
arteries, and arcuate arteries. Interestitial fibrosis and tubular
atrophy were graded as follows: grade 0, normal; grade 1,
<20% tissue involved; grade 2, 20% through 40% involvement;
Table 1. Categories of idiopathic renal vasculitis with
glomerulonephritis
Involvement
Group I
108 pt
Group 2
33 pt
Group 3
29 pt
Total
170 pt
Glomerular 108 33 29 170
capillaries
Small arteries or
arterioles
Renal — 31 16 47
Extrarenal 17
Medium-sized
arteries
Renal — 21C 21
Extrarenal — 10
Patients with 21 19 17 57
extrarenal
biopsies
a A patient may be represented in more than one row because both
renal and extrarenal tissues of various sizes may be involved. Entries
are number of patients with finding.
b Skin
C Large intralobular or arcuate arteriesd Muscle in eight patients, lung in two
grade 3, 41% through 70% involvement; and grade 4, >70%
involvement.
Group class (fication
Patients were placed into three groups (Table 1): group 1,
focal segmental necrotizing gbomerubonephritis alone; group 2,
focal segmental necrotizing glomerulonephritis combined with
involvement of aterioles and/or small interlobular arteries
(<200 itm); and group 3, focal segmental necrotizing gbomeru-
lonephritis combined with involvement of large interlobular
and/or arcuate arteries and/or extrarenal medium-sized arteries.
Follow-up of patients
Follow-up data were obtained from at least two of three
sources: review of the patient's Mayo Clinic record, follow-up
letter, and contact with the patient's physician. If a serum
creatinine determination was not available within the previous
six months, a determination was made from a serum sample
obtained in the patient's home community and mailed to our
institution for analysis.
Statistical methods
The statistical methods employed were rank-sum tests and
contingency table analysis. In the analysis of patient survival
and survival free of renal failure, the Kaplan-Meier [17] tech-
nique was used to estimate survival. All patients were included
in the analysis of patient and renal survival.
A Cox proportional-hazard survival analysis [18] was per-
formed to assess the prognostic value of the different predictor
variables. The approach to the selection of the predictor vari-
ables was a backward stepwise deletion of the most nonsignif-
icant predictor variables. Deletion of variables was based on the
computed significance probability after accounting for all other
predictors in the model. This allowed the identification of a
subset of variables that had significant independent association
with the two end points. The P values reported for predictors
correspond to the importance of the variable in predicting an
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Table 2. Renal biopsy findings at presentation in 170 cases of idiopathic renal vasculitisa
Group 1
108 pt
Group 2
33 pt
Group 3
29 pt
Total
170 pt
Total no. of glomeruli" 24 (4—124) 22 (2—84) 23 (4—100) 23 (2—124)
% glomeruli sclerosed 26 (0—83) 22 (0—80) 22 (0—83) 24 (0—83)
% glomeruli with active 34 (0—83) 29 (0—81) 31 (0-100) 32 (0—100)
segmental necrotizing
lesions
% glomeruli with 21 (0—92) 14 (0—60) 9 (0—64) 18 (0—92)
crescents
Interstitial fibrosis and
tubular atrophy
gradec
0, normal 11% 12% 4% 10%
1, <20% involved 47% 46% 41% 46%
2, 20—40% involved 34% 33% 45% 36%
3, 41—70% involved 8% 9% 10% 8%
4, >70% involved 0% 0% 0% 0%
a The three groups were compared overall (rank-sum test for multiple samples) followed by pair-wise comparisons of each group. For the
maximal grade of interstitial fibrosis and tubular atrophy, a chi-square test of association was employed. No significant differences were noted for
the total number of glomeruli, percent glomeruli sclerosed, percent glomeruli with active segmental necrotizing lesions, or the maximal grade of
interstitial fibrosis and tubular atrophy. The mean percent glomeruli with crescents was significantly different among the three groups (P < 0.001),
with group 1 significantly higher than group 2 (P = 0.038) and group 3 (P < 0.001).b Mean (range).
Each feature was graded separately. Presented is the maximal grade.
increased hazard for patient survival or survival free of renal
failure after accounting for all other predictors in the model
under consideration.
For studying the association between the two major epd
points (patient survival and survival free of renal failure),
continuous predictor variables were also assessed with the Cox
proportional-hazard model and subsequently put into sub-
groups of the continuous variable for graphic display. Survival
of subgroups of patients was compared using the log-rank test
[191.
Results
The severity of renal insufficiency was different for the three
groups. The median serum creatinine values were 2.6, 2.2, and
1.6 for groups 1, 2, and 3, respectively (P = 0.04), indicating
that patients with glomerular and small-vessel involvement had
a higher degree of renal function impairment at presentation.
There were 142 closed renal biopsies and 28 open renal
biopsies. The number of glomeruli in the renal biopsy speci-
mens ranged from 2 to more than 100; the mean number was
similar for the three groups (Table 2). Only three biopsy
specimens contained less than five glomeruli, one specimen in
each of the three groups. There were no significant differences
among the groups in the percentage of totally sclerotic glomer-
uli, glomeruli with active segmental necrotizing lesions, or
average number of cellular or fibrous crescents. There were
small differences in grades of interstitial involvement among the
three groups. Thirty-nine (27%) of the 142 patients who had
closed renal biopsies showed vasculitis beyond the glomerular
capillaries, compared with four (14%) of the 28 patients who
had open renal biopsies. The difference was not statistically
significant, although more patients with closed renal biopsies
tended to have arterial vasculitis, compared to those with open
renal biopsies.
Immunofluorescent findings
Immunofluorescence was performed on 129 renal biopsy
tissues. Findings were negative in 55 specimens, while 74
(group 1, 55; group 2, 12; group 3, 7) showed immunoglobulin
deposition with or without complement component deposition,
usually in a focal and segmental pattern. Sixty of these speci-
mens showed only small, scattered deposits graded trace to 1+,
while 11 specimens showed scattered deposits graded 2+ to 3+
involving some but not all glomeruli. Only three specimens
showed diffuse and generalized immunofluorescent findings
graded 3+ involving all glomeruli. Based on immunofluores-
cence, 3 of 129 patients had definite evidence of immune-
complex-mediated disease and 11 patients had findings sugges-
tive of it. The immunofluorescence findings in the other 60
patients are of doubtful significance.
Leukocytosis
Of the 168 patients with leukocyte count determinations, 42
had leukocytosis (leukocyte count >12 x 103/mm3). Only one
of the 42 patients had evidence of bacterial infection in the form
of a localized wound infection. None of these patients was
receiving prednisone or other immunosuppressive therapy; all
had active disease consistent with vasculitis. Of these 42
patients, 35 (83%) had neutrophilia (defined as granulocytes
comprising >73% of the leukocytes in the peripheral blood).
Association between renal function and biopsy findings at
presentation
We assessed the association between serum creatinine level
at presentation and percentage of sclerosed glomeruli. The rank
correlation was 0.32 (P < 0.001). There were 30, 82, and 58
patients with sclerosed glomeruli of 0%, 1 to 30%, and 31%,
respectively. The median serum creatinine level was 1.6, 2.0,
1136 Wilkowski et a!: Idiopathic renal vasculitis and GN
and 3.6, respectively. In a similar fashion, we also assessed the
association between serum creatinine level at presentation and
percentage of crescentic glomeruli. The rank correlation was
0.30 (P < 0.001). There were 56, 78, and 36 patients with
crescentic glomeruli of 0%, 1 to 30%, and 3 1%, respectively.
For these groups, the median serum creatinine level was 1.5,
2.6, and 3.1 mg/dl, respectively. Thus, at presentation, there is
a positive correlation between the serum creatinine level and: 1)
the percentage of sclerosed glomeruli; and 2) the percentage of
crescents.
Treatment
During the calendar period included in this study, the treat-
ment for these conditions has remained basically unchanged.
We relied on a high daily oral dose of prednisone; four patients
received "pulsed" intravenously administered methylprednis-
olone; none of the patients had plasmapheresis.
Treatment with prednisone or prednisone and cytotoxic
drugs was documented in 154 of the 170 cases. For eight
patients, treatment with prednisone was prescribed, but it could
not be confirmed that these patients received the medication.
Six patients with far advanced disease and one patient with
tuberculosis received no treatment, whereas one patient re-
ceived dipyridamole and aspirin. Most of the prednisone-
treated patients (138 of 154) initially received high-dose pred-
nisone, defined as 60 mg a day, while 16 patients received 40
to 59 mg a day. The percentage of patients receiving prednisone
in each group was not significantly different. The doses of
prednisone were gradually reduced, with patients maintained
on prednisone therapy for variable periods.
All but four patients treated with cytotoxic drugs received the
medication for more than six weeks. Thirty-two patients were
treated with cyclophosphamide, while 15 received azathioprine.
Outcome
Of the 170 patients, 67 were known to have died, 13 of whom
reached end-stage renal failure (defined as a creatinine level
 10 mg/dl, renal transplantation, or chronic dialysis) before
death. Thirty patients died within the first year of presentation
(3 of which had previously reached end-stage renal failure) and
37 patients died thereafter (10 of which had previously reached
end-stage renal failure). Overall to date, 22 patients have
reached end-stage renal failure, five within one year.
Survival
For survival analysis, we considered, as was done in previous
reports [20—22], two end points: survival to death from any
cause and survival to the first occurrence of either end-stage
renal disease or death. Survival free of renal failure was used to
describe the latter end point. We believe this is a conservative
approach to the renal failure end point.
Curves for overall patient survival and survival free of renal
failure for the 170 patients indicate that deaths occurred at a
faster rate during the first year than during subsequent periods
(Fig. lA). Patient survival was 86% at six months, 81% at one
year, 61% at five years, and 44% at 10 years. For patients who
survived two years, subsequent survival was closer to that
expected in the general population of persons of like gender and
age, indicating that the period at higher risk for death is within
the first two years of presentation. There were no significant
I I I
I I I I
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Time, years
Fig. 1. A. Expected patient survival (—) and survival free of renal
failure or death (—) after diagnosis was confirmed by histologic study
(—), N = 170. Expected survival is based on patients of similar gender,
age, and calendar year of birth from the general population of the West
North Central region of the United States. Data include deaths from all
causes. In parentheses are the number of patients at risk for the
respective events and being followed at 1, 3, and 5 years. Overall
patient survival was 81% at 1 year and 61% at 5 years, significantly less
than the expected survival. B. Patient survival for the three groups.
There were no significant differences in patient survival between groups
(log-rank). Group I patients, N = 108 (—) had focal segmental necro-
tizing glomerulonephritis; group 2, N = 33 (—), had focal segmental
necrotizing glomerulonephritis and small-vessel vasculitis, and group 3,
N = 29 (—), had focal segmental necrotizing glomerulonephritis and
medium-sized artery vasculitis. C. Survival free from renal failure for
each of the three groups. There were no significant differences between
groups (log-rank).
differences in patient survival among the three groups (Fig. 1B).
Within the first year, however, patients of group 3 tended to
have a higher mortality rate than did patients in the other two
groups, but the differences were not statistically significant.
Curves for survival free of renal failure were not significantly
different for the three groups (Fig. 1C). This analysis shows that
the overall patient survival in idiopathic renal vasculitis was
61% at five years and 44% at ten years, compared with expected
rates of 90% and 78% at five and ten years, respectively, for the
general population of the West North Central region of the
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Table 3. Analysis of risk factors for patient and renal survival in idiopathic renal vasculitis
Patient survival % Survival free of renal failure %
PP
N 1 yr 3 yr 5 yr valuea 1 yr 3 yr 5 yr valuea
Age yr
29 17 94 85 85 0.008 94 77 77 0.015
30—39 13 83 83 83 83 83 83
40—49 9 100 100 100 89 89 89
50—59 45 82 71 67 80 61 54
60—69 51 70 61 42 64 54 38
70+ 35 81 66 61 81 66 55
Leukocyte count XJO/mm3
6 18 89 82 74 0.055 89 76 53 0.071
>6 to 8 45 91 79 72 91 74 70
>8 to 10 29 82 70 58 78 62 52
>10 to 12 34 83 75 59 74 66 55
>12 to 16 25 72 67 61 72 67 55
>16 17 57 41 33 53 38 30
Serum creatinine mg/dl
<2.0 67 84 75 68 0.080 82 71 67 <0.001
2.0—3.9 53 79 71 67 79 69 62
4.0—5.9 24 83 62 40 78 58 34
6.0—9.9 16 60 60 60 61 52 42
10.0+ 10 90 77 41 60 40 15
Hypertension
No 129 81 71 65 0.037 78 67 60 0.018
Yes 41 79 69 47 77 58 36
Age yr 170 0.006 0.023
Leukocyte count lO/mm3 168 0.008 0.028
Serum creatinine mgI dl 170 0.020 0.001
Biopsy findings
No. of glomeruli 170 >0.10 0.056
% of glomeruli involved 169 >0.10 >0.10
% of glomeruli sclerosed 170 >0.10 >0.10
% of glomeruli with active 168 0.012 0.031
generalized lesions
% of glomeruli with active 167 >0.10 >0.10
segmental lesions
% of glomeruli with 170 >0.10 >0.10
crescents
% of glomeruli with 168 >0.10 >0.10
fibrotic crescents
Interstitial fibrosis and 170 0.068 0.038
tubular atrophyb
a Two-tail P values from log-rank for discrete variables and Cox's proportional-hazards model for continuous variablesb Each feature was graded separately on a 0 to 4 scale. The scale values were 0 (none), 1 (<20% involved), 2 (20—40% involved), 3 (41—70%
involved), and 4 (71 +% involved). The maximum score for the two features was used in the analysis.
United States for persons of similar age, gender, and calendar
year of birth [23]. It also shows that the outcomes for the two
survival end points were similar for the three diagnostic cate-
gories of idiopathic vasculitis. Thus, the prognosis for idio-
pathic vasculitis is serious, regardless of the size of vessels
involved.
Riskfactors for patient survival and survival free of renal
failure
Leukocyte count, patient age, and serum creatinine level,
analyzed as continuous variables, and hypertension were sig-
nificant predictors of patient survival and survival free of renal
failure (Table 3, Fig. 2). The maximal grade of tubular atrophy
and interstitial fibrosis, when analyzed as a continuous variable,
was a significant predictor for survival free of renal failure (P =
0.035). To study the association between survival free of renal
failure and maximal involvement of glomeruli with crescents or
sclerosis, we analyzed subgroups defined as patients having
involvement of less than 20%, 20 through 39%, 40 through 59%,
60 through 79%, and 80% or more. In addition, we compared
those patients who were above and below each of these break
points. Furthermore, we assessed the association using Cox's
proportional-hazard model, treating the maximal glomeruli in-
volved as a continual variable. Although no statistically signif-
icant associations were detected in any of these analyses, the
survival curves showed a trend for poorer survival free of renal
failure in the groups with the higher percentage of glomeruli
involved. For the comparison of the group with <40% involve-
ment to the group with >40% involvement, the findings were
consistent, with a poorer prognosis for patients who had greater
involvement with either sclerosis or crescents. For the 113
patients with <40% involvement, the five-year survival rate
was 58%, while for the 57 patients with 40% involvement, the
rate was 48%. The log-rank test yielded P = 0.057 in the
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Fig. 2. Observed patient surviva! (A) and survival free from rena!
failure (B) according to groupings of age, !eukocyte count, serum
creatinine level, and presence of hypertension. Analyzed as continuous
variables, these are significant predictors of patient survival and sur-
viva! free of renal failure. Estimated 5-year patient survival for these
four risk factors univariately was 88% for age s49 years vs. <54% for
o!der patients (P < 0.00!), 33% for pronounced leukocytosis ( 16,000/
mm3) vs. 65% for lower counts (P = 0.004),46% for patients with serum
creatinine level e4.0 mg/dl vs. 68% for levels <4.0 mgldl (P = 0.005),
and 47% for hypertensive patients vs. 65% for normotensive patients (P
< 0.037). Estimated 5-year survival free of renal failure was 83% vs.
48% (P C 0.001), 30% vs. 58% (P = 0.008), 32% vs. 65% (P C 0.001),
and 36% vs. 60% (P = 0.018) for the same groups of age, leukocytosis,
serum creatininc level, and blood pressure.
analysis of the overall curves. One of the explanations for the
lack of a statistically significant association between survival
free of renal failure and the maximal involvement with either
crescents or sclerosis is the few (3.5%) patients with >75%
involvement. Only 25% of the patients had 50 glomeruli
involved, while the median was 28% for the whole group.
Twenty-one patients had neurologic involvement, either cen-
tral or peripheral. These patients had poorer survival (P =
0.003) or survival free of renal failure (P = 0.023) than those
without neurologic involvement. The percentage of glomeruli
with active generalized lesions was also associated with poor
outcome for patient survival (P 0.012) and survival free of
renal failure (P = 0.030). We believe this association is the
result of a few patients with very high percentages of general-
ized glomerular lesions who did poorly. This small number of
patients precluded extensive investigation in a multivariate
model. Other discrete and continuous variables that did not
have significant predictive value for either end point were fever,
constitutional symptoms, pulmonary, gastrointestinal, and cu-
taneous findings, arthritis, hemoglobin, platelet count, and
sedimentation rate. Only 8% of the patients in this study had
oligoanuria or required dialysis (or both). Of five patients
presented with oligoanuria, two were dead in less than one year
(N) and three have survived (one with end-stage renal failure).
(131) Thirteen patients required either hemodialysis or peritoneal
dialysis at presentation; seven are dead and six have survived
(three of these are in end-stage renal failure). Thus, oligoanuria
or need for dialysis (or both) carries a high risk for death or
renal failure.
To display the predictive value for the two end points,
Kaplan-Meier survival curves were developed according to age
intervals, degree of leukocytosis, renal insufficiency, and pres-
ence of hypertension (Fig. 2). Finer divisions of these risk
factors are shown in Table 3.
The subdivisions of serum creatinine levels shown in Table 3
demonstrate that, in terms of predicting long-term outcome of
both patient survival and renal function, a serum creatinine
level of 4.0 has as bad an implication as does a serum
creatinine level of 6.0, a widely accepted level of a poor
prognosis. For this reason, we selected a serum creatinine level
of 4 mg/dl for univariate and multivariate display of the
findings.
Patients 49 years of age and younger had an estimated
five-year patient survival of 88%, compared with 54% for older
patient groups. Patients with pronounced leukocytosis
(>16,000/mm3) had the highest mortality rate, particularly early
during the course of the disease; one year survival was only
57% and decreased to 33% at five years. Advanced renal
insufficiency, defined as a serum creatinine level 4 mgldl, was
associated with a poor outcome. The five year survival was
46%, and five year survival free of renal failure was 32% in
patients with serum creatinine levels 4.0 mg/dl, while it was
68% and 65%, respectively, for lesser degrees of renal function
loss.
Multivariate analysis
Stepwise modeling procedures selected two variables as
independent and additive predictors for either patient survival
or survival free of renal failure: leukocyte count and serum
creatinine level. The intervals for leukocyte count and serum
creatinine level, although somewhat arbitrary, were chosen
based on numerous analyses of various subgroups. Multivariate
analysis of leukocyte count and serum creatinine level as risk
factors was performed by considering the influence of sequen-
tial intervals of serum creatinine level and leukocyte counts
within the range of values observed in this study. In patients
with a serum creatinine level of <4 mg/dl, the effect of increas-
ing levels of leukocyte counts was significantly associated with
poorer outcomes for both patient survival (P 0.006) and
survival free of renal failure (P = 0.024). The most dramatic
impact is seen in patients with counts >16,000/mm3, although
there seems to be an incremental risk at lesser counts. Figure 3
summarizes patient survival for these subgroups. In patients
with a serum creatinine level 4.0 mg/dl, the impact of leuko-
cyte count was not evident. The observed outcomes for the two
end points were worse for patients with lower serum creatinine
levels (<4.0 mgldl) and high leukocyte counts (>16,000/mm3)
than for those with serum creatinine levels 4.0 mg/dl. Figure
4 similarly displays data on survival free of renal failure for
these subgroups.
Both the Cox model and the graphic display support the
hypothesis that leukocytosis has significant independent predic-
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tive value after adjustment for the influence of renal insuffi-
ciency.
Discussion
This study demonsirates that leukocytosis and serum creati-
nine levels are the most important predictors of patient survival
and survival free of renal failure in patients with idiopathic renal
vasculitis and glomerulonephritis. Multivariate analysis demon-
strated that leukocyte count and serum creatinine level each
had simultaneously independent predictive value for both end
points. Univariate analysis identified leukocytosis, advanced
renal insufficiency, older age, and hypertension as predictors
for these two end points (Fig. 2). The importance of leukocy-
tosis as a risk factor is highlighted in those patients with lower
levels of serum creatinine and pronounced leukocytosis who
had the worst prognosis in this study (Figs. 3 and 4). This new
risk factor in patients with idiopathic renal vasculitis and
glomerulonephritis is important because it may identify patients
at risk early during the course of renal involvement. This study,
however, does not establish a causal relationship between
leukocyte count and progression of injury.
The leukocytosis of patients in this study was due to in-
creased numbers of polymorphonuclear leukocytes in the ab-
sence of an infectious process. Leukocytosis may be relevant to
treatment intervention. For instance, corticosteroids decrease
leukocyte accumulation at an inflammatory site, because of a
decrease in responsiveness to chemostatic stimuli [24], and the
anti-inflammatory properties of the antimetabolites are primar-
ily attributed to their effects on marrow proliferation and,
consequently, on the number of circulating leukocytes [25].
Glucocorticoids are the primary treatment in renal vasculitis
[4], and cyclophosphamide has been shown to have beneficial
therapeutic effects greater than those achieved with corticoste-
roids alone [3]. The effects of cyclophosphamide may be due, at
100
80
60
40
20 —
-I
— Serum creatinine <4
WBC8 (N = 49) - —.
8<WBC12(N = 42)
12<WBC16 (N = 17)
WBC>16 (N = 10) ——
Serum creatinine 4 (N 50) —
0)
0)
a)
C
a,
0
0)
a)
>
Cl)
a)
>
03
C
0)
a)
a-
0
100
80
Time, years
60
40 —
20 —
Fig. 3. Patient survival for groups defined by
selected combinations of signifi cant risk
factors. Two patients with serum creatinine
levels <4 mg/dl are missing. In patients with
serum creatinine levels <4 mg/dl, the effect of
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least in part, to the reduction of the leukocyte count [26]. Thus,
patients with idiopathic renal vasculitis and pronounced leuko-
cytosis may be prime candidates for more aggressive treatment.
Leukocytosis may be controlled by cyclophosphamide and by
pulse-administered methyiprednisolone, which can reduce leu-
kocyte accumulation at inflammatory sites.
The three groups of patients described in this study were
defined on the basis of the size of vessel involved in tissue
biopsies covering a range from capillaries to medium-sized
arteries, No etiologic factors were apparent in these patients,
and other well-recognized diseases associated with vasculitis
were excluded. We do not propose a new classification of renal
vasculitis but rather emphasize the wide spectrum and the
continuum of inflammatory changes involving the vascular tree.
Such risk factors as oligoanuria and need for dialysis are
associated with poor outcome, although only 8% of patients
presented with these features. Likewise, a few patients (23%)
presented with neurologic findings that were associated with
poor outcomes. The severity of tubular atrophy and interstitial
fibrosis was a significant predictor for survival free of renal
failure but did not have independent predictive value when
analyzed simultaneously with other variables in a multivariate
model. Patients with a very high percentage of active general-
ized glomerular lesions had a poor outcome, but only a small
number of patients had this finding. Other morphologic varia-
bles such as percentage of sclerosed glomeruli and percentage
of crescents showed a positive correlation with serum creati-
nine level at the time of initial evaluation. It should be empha-
sized that the survival curves indicated a trend for poorer
outcome regarding survival free of renal failure in those patients
with >40% of glomeruli involved with either crescents or
sclerosis.
Patients with biopsy evidence of idiopathic renal vasculitis—
that is, focal segmental necrotizing glomerulonephritis alone,
focal segmental necrotizing glomerulonephritis with small-
vessel vasculitis, or focal segmental necrotizing glomerulone-
phritis with medium-sized vessel vasculitis—had comparable
patient survival and survival free of renal failure at one, five and
ten years. Most deaths occurred within the first year of follow-
up.
Considerable overlap of clinical, laboratory, and pathologic
findings existed in the three groups, indicating that classification
into specific categories of idiopathic renal vasculitis may not be
realistic. The degree of morphologic overlap in idiopathic
vaseulitis recognized by other authors [5, 10, 271 has been
confirmed in this study, specifically in patients with glomerulo-
nephritis. Group 3 comprised 29 patients with vasculitis involv-
ing extrarenal medium-sized arteries as well as arcuate and
interlobular renal arteries, findings consistent with polyarteritis
nodosa. Because angiography was not performed, this study did
not include patients with polyarteritis nodosa without glomer-
ulonephritis. Patients with Wegener's granulomatosis may have
been included in this study because focal segmental necrotizing
glomerulonephritis is also a typical feature of this disease. This
is unlikely, however, because patients with pulmonary or upper
respiratory findings suggestive of Wegener's granulomatosis
had negative tissue biopsy (lung biopsies in 10 and upper
respiratory tract biopsies in 9).
In conclusion, this analysis shows that risk factors such as
leukocytosis and serum creatinine level are important prognos-
tic indicators. The presence of leukocytosis in the absence of
renal insufficiency places these patients at a very high risk for
both death and renal failure. This study also showed no
difference in patient survival or survival free of renal failure in
three groups of patients with idiopathic renal vasculitis and
glomerulonephritis in terms of the size of vessel involved.
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